Status and phase
Conditions
Treatments
About
The efficacy and safety of the use of Camrelizumab combined with Apatinib
Full description
To evaluate the clinical efficacy and safety of Camrelizumab combined with Apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer.
The 62 patients were enrolled in a 2-week regimen with 200mg Camrelizumab given intravenously every two weeks and 250mg apatinib mesylate every 4 weeks for a treatment cycle until progressive or intolerable,then the objective remission rate(ORR) was calculated.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age 18 - 75 years;
Patients with histologically or cytologically confirmed advanced or metastatic gastric cancer and colorectal cancer.
Patients who had previously progressed after receiving standard second-line advanced treatment;
Patients with at least one evaluable or measurable lesions as per RECIST version 1.1 (CT scan length and diameter of tumor lesion≥10mm,CT scan of lymph node lesion was short diameter≥15mm,scan slice thickness 5mm;)
ECOG performance status (PS) 0 - 2;
Life expectancy of at least 3 months;
Patients with adequate organ function at the time of enrollment as defined below:
Blood routine examination standard:(without blood transfusion within 14 days before enrollment)
Biochemical examination shall meet the following standards:
Women of childbearing age in the serum or urine pregnancy test is negative within 7 days prior to study enrollment and must be Non-lactating patients,and agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during the study period and within 8 months after the end of the study; males should agree to patients who must use contraception during the study period and within 8 months after the end of the study period
Subjects voluntarily joined the study, signed informed consent, good compliance, and followed up;
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
62 participants in 1 patient group
Loading...
Central trial contact
Li Xiao, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal